CO14 Patient-Reported Outcomes (PROS) With Ramucirumab Versus Placebo in Chinese Patients With Hepatocellular Carcinoma (HCC) and Elevated Alpha-Fetoprotein From the Randomized Phase 3 Reach-2 Study
Abstract
Authors
X Chen G Shao Y Bai S Gu K Gu Q Zhang W Zhang J Liu L Zhou S Qin